Phathom Pharmaceuticals, Inc. (PHAT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Phathom Pharmaceuticals, Inc. reported revenue of $175.11M, up 216.9% from the prior year. The company ran a net loss, with a net margin of -126.3% and a gross margin of 87.1%. It held $259.15M in total assets against $697.32M in total liabilities.
Key ratios (FY2025)
87.1%
Gross margin
-91.4%
Operating margin
-126.3%
Net margin
+216.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $175.11M | $55.25M | $682.0K | $0 | — | — | — | — | — |
| Cost of Revenue | $22.60M | $7.97M | $167.0K | $0 | — | — | — | — | — |
| Gross Profit | $152.51M | $47.28M | $515.0K | $0 | — | — | — | — | — |
| Operating Income | -$159.99M | -$277.47M | -$167.31M | -$172.44M | -$135.08M | -$125.67M | -$106.22M | -$1.23M | — |
| Net Income | -$221.25M | -$334.33M | -$201.59M | -$197.72M | -$143.88M | -$129.07M | -$255.13M | -$1.29M | — |
| EPS (Diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 | — | — | — | — |
| Total Assets | $259.15M | $378.32M | $413.84M | $164.81M | $189.43M | $295.11M | $257.18M | $902.0K | — |
| Total Liabilities | $697.32M | $631.90M | $486.60M | $239.62M | $117.28M | $100.84M | $29.22M | $2.19M | — |
| Shareholders' Equity | -$438.17M | -$253.58M | -$72.76M | -$74.81M | $72.16M | $194.27M | $227.96M | -$1.29M | $0 |
| Cash & Equivalents | $129.97M | $297.26M | $381.39M | $155.38M | $183.26M | $287.50M | $243.76M | $879.0K | — |
| Operating Cash Flow | -$166.78M | -$266.77M | -$137.58M | -$146.53M | -$148.46M | -$69.69M | -$36.51M | -$1.02M | — |
| Capital Expenditures | $229.0K | $135.0K | $1.63M | $1.04M | $328.0K | $1.04M | $132.0K | — | — |
| Shares Outstanding | 71.42M | 68.52M | 57.97M | 41.47M | 30.51M | 28.52M | 24.73M | — | — |